CREDIT CARDS ACCEPTED | 6% OFF CRYPTO | 3RD-PARTY TESTING (JANOSHIK)
Menu
Cart
Cagrilintide + Semaglutide Blend 10mg / 10mg
Cagrilintide certificate of analysis
Cagrilintide hplc
semaglutide certificate of analysis
semaglutide hplc

Cagrilintide + Semaglutide Blend 10mg / 10mg

$633.00

Cost per vial $: 63.3

Cagrilintide + Semaglutide blend minimum order quantity is one box (10 vials x 10/10mg). All orders are shipped wholesale in unbranded packaging. Worldwide 7 – 14 day shipping to the USA, UK, AUS & NZ.

Bulk discounts
Quantity Bulk Discount Price
2 5% $601.35
3-5 8% $582.36
6-10 11% $563.37
SKU: CAGSEM10 Category:

Description

Semaglutide (sold under the brand names Wegovy/Ozempic) is a peptide that helps manage blood sugar levels and support weight loss by mimicking a natural hormone that regulates appetite and glucose. Cagrilintide is another, newer-generation weight loss peptide that works through a different mechanism, which is why the two are often combined for greater weight loss. This blend of semaglutide and cagrilintide is the generic version of CagriSema.

Minimum order quantity: one box (10 vials x 10mg / 10 mg).

Additional information

Purity

≥99.0%
Molar Mass

4113.64 g/mol
4409.1 g/mol
Molecular Formula

C187H290N45O59
C194H312N54O59S2
Sequence

{Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (Disulfide bridge:Cys3-Cys8)

H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Cost per vial $

63.3
  1. Apovian, Caroline M., and Marie E. McDonnell. "CagriSema and the link between obesity and type 2 diabetes." The Lancet 402.10403 (2023): 671-673.
  2. Frias, Juan P., et al. "Efficacy and safety of co-administered once-weekly cagrilintide 2· 4 mg with once-weekly semaglutide 2· 4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial." The Lancet 402.10403 (2023): 720-730.
  3. Jacobsen, Julie. "CagriSema Attenuates Metabolic Adaptation Associated With Weight Loss in Diet-Induced Obese Rats." Obesity 30 (2022): 132-132.
  4. Dutta, Deep, et al. "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis." Indian Journal of Endocrinology and Metabolism (2024): 10-4103.
  5. Mikhail, N., and S. Wali. "Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes." Clinical Trials and Clinical Research 2.5 (2023).

CAGRILINTIDE COA

CAGRILINTIDE HPLC

SEMAGLUTIDE COA

SEMAGLUTIDE HPLC

Related products